Melanie Royce

4.3k citations

93 papers · 3.1k indexed · h-index 30

Impact in

Cancer Research top 1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways

Papers in

Oncology 69
- Cancer Treatment and Pharmacology 26
- HER2/EGFR in Cancer Research 22
- Global Cancer Incidence and Screening 11
- Colorectal Cancer Treatments and Studies 11
Cancer Research 38
- Breast Cancer Treatment Studies 36

Co-authors: Gabriel N. Hortobágyi Vicente Valero Georges Vlastos Vincent Vinh‐Hung Patricia Tai Jeffrey S. Ross Lajos Pusztai Banu Arun
Journals: Journal of Clinical Oncology (19 papers)Breast Cancer Research and Treatment (8 papers)Cancer Research (4 papers)BMC Cancer (3 papers)Cancer (2 papers)
Partner nations: United States Switzerland Canada

In The Last Decade

Melanie Royce

89 papers receiving 3.0k citations

Peers

Countries citing papers authored by Melanie Royce

Since Specialization

Citations

This map shows the geographic impact of Melanie Royce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie Royce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie Royce more than expected).

Fields of papers citing papers by Melanie Royce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melanie Royce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie Royce. The network helps show where Melanie Royce may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Melanie Royce, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Melanie Royce Line = papers co-authored together Melanie Royce links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	FDA Approval Summary: Capecitabine Labeling Update under Project Renewal Clinical Cancer Research ·Sundeep Agrawal, Chiyo Onoue, William F. Pierce, J Andrade Jardi, Jahanzaib Jafar, Melanie Royce, Christy Osgood, Laleh Amiri‐Kordestani, Haw-Jyh Chiu, Tiffany K. Ricks, Sutriani Shafa, Jeanne Fourie Zirkelbach, Rosane Charlab, Michael Pacanowski, Tamy Kim, Richard Pazdur, Paul G. Kluetz, Jennifer Gao	2024	0
2	Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna Wedam, Melanie Royce, RH Goldblatt, Christy Osgood, Gwynn Ison, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani	2021	21
3	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group Journal of Clinical Oncology ·Roisín M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown‐Glaberman, Bernhard Heininger, Bryan A. Faller, Adedayo A. Onitilo, Mark E. Burkard, G. Thomas Budd, Ellis Levine, Melanie Royce, Peter A. Kaufman, Alexandra Thomas, Jane B. Trepel, Antonio C. Wolff, Joseph A. Sparano	2021	76
4	Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics npj Breast Cancer ·Cindy K. Blair, Charles L. Wiggins, Andrea M. Nibbe, Н. В. Селезнёва, Eric R. Prossnitz, Melanie Royce, Lesley Lomo, Deirdre A. Hill	2019	79
5	Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort study PLoS ONE ·Deirdre A. Hill, Eric R. Prossnitz, Melanie Royce, Andrea M. Nibbe	2019	19
6	Breast cancer survival, survival disparities, and guideline-based treatment Breast Cancer Research and Treatment ·Deirdre A. Hill, Paul Benedict, Lesley Lomo, Charles L. Wiggins, Marc Barry, Eric R. Prossnitz, Melanie Royce	2018	38
7	Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer Cancer Treatment Reviews ·Joyce O’Shaughnessy, J. Thaddeus Beck, Melanie Royce	2018	43
8	Estrogen receptor quantitative measures and breast cancer survival Breast Cancer Research and Treatment ·Deirdre A. Hill, Marc Barry, Charles L. Wiggins, Andrea M. Nibbe, Melanie Royce, Eric R. Prossnitz, Lesley Lomo	2017	20
9	BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC) Annals of Oncology ·Melanie Royce, Т. П. Ванченко, Mustafa Özgüroğlu, Thomas Bachelot, Sérgio Jobim Azevedo, J Handelsman David, Roberto Hegg, Marc Debled, WJ Gradishar, C. Manlius, Antonia Ridolfi, Jaw‐Town Lin, François Ringeisen, Fátima Cardoso	2016	11
10	HER2-targeted therapy for early-stage breast cancer: a comprehensive review. PubMed ·Ursa Brown‐Glaberman, Zoneddy Dayao, Melanie Royce	2014	20
11	Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy Medical Oncology ·Soley Bayraktar, Melanie Royce, Lisette Stork‐Sloots, Femke De Snoo, Stefan Glück	2014	14
12	Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial The Lancet Oncology ·Aman U. Buzdar, Vera J. Suman, Funda Meric‐Bernstam, A. Marilyn Leitch, Matthew J. Ellis, Judy C. Boughey, Gary Unzeitig, Melanie Royce, Linda McCall, Michael S. Ewer, Kelly K. Hunt	2013	120
13	Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer BMC Cancer ·Hugo Arias‐Pulido, Graziela Pereira Pestana de Castro, Yun Gong, Clifford Qualls, 刘四清, Melanie Royce	2012	37
14	Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients Breast Cancer Research and Treatment ·Graziela Pereira Pestana de Castro, Hugo Arias‐Pulido, Macks Wendhel Gonçalves, Clifford Qualls, 김경제, Claire F. Verschraegen, Anne M. Wallace, Melanie Royce	2011	24
15	Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer Clinical Cancer Research ·Massimo Cristofanilli, Vicente Valero, Aroop Mangalik, Melanie Royce, Ian Rabinowitz, Francis P. Arena, Joan F. Kroener, V. Kulinkovich, Claire Watkins, Sarah Bacus, Elsa M. Cora, Elizabeth J. Anderson, Patrick Magill	2010	134
16	The Effect of Adjuvant Radiotherapy on Mortality Differs According to Primary Tumor Location in Women with Node-Positive Breast Cancer Strahlentherapie und Onkologie ·Vincent Vinh‐Hung, Pauline T. Truong, Wolfgang Janni, Nam P. Nguyen, Georges Vlastos, Gábor Cserni, Melanie Royce, Wendy A. Woodward, Nikola Rykalská, Patricia Tai, Guy Soete, Micaela Jennifer Cosgrove, B. Cutuli, Guy Storme, Christine Bouchardy	2009	12
17	Modeling the effect of age in T1-2 breast cancer using the SEER database BMC Cancer ·Patricia Tai, Gábor Cserni, Jan Van de Steene, Georges Vlastos, Mia Voordeckers, Melanie Royce, Sang-Joon Lee, Vincent Vinh‐Hung, Guy Storme	2005	36
18	Ratios of involved nodes in early breast cancer Breast Cancer Research ·Vincent Vinh‐Hung, Claire F. Verschraegen, Nikola Rykalská, Gábor Cserni, Jan Van de Steene, Patricia Tai, Georges Vlastos, Mia Voordeckers, Guy Storme, Melanie Royce	2004	142
19	Capecitabine for 5-Fluorouracil-Resistant Brain Metastases From Breast Cancer American Journal of Clinical Oncology ·K.D. Neumann, W. K. Alfred Yung, Melanie Royce, Donald F. Schomer, Richard L. Theriault	2001	74
20	Novel oral chemotherapy agents Current Oncology Reports ·Melanie Royce, Paulo M. Hoff, Richard Pazdur	2000	5

About Melanie Royce

Melanie Royce is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Dermatology, having authored 93 papers that have together received 3.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (36 papers), Cancer Treatment and Pharmacology (26 papers), HER2/EGFR in Cancer Research (22 papers), Advanced Breast Cancer Therapies (13 papers), Global Cancer Incidence and Screening (11 papers), Colorectal Cancer Treatments and Studies (11 papers), Breast Lesions and Carcinomas (10 papers) and Estrogen and related hormone effects (9 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.8k citations), Pulmonary and Respiratory Medicine (700 citations), Pathology and Forensic Medicine (364 citations) and Molecular Biology (978 citations). Melanie Royce has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include Gabriel N. Hortobágyi, Vicente Valero, Georges Vlastos, Vincent Vinh‐Hung, Patricia Tai, Jeffrey S. Ross, Lajos Pusztai, Banu Arun, Daniel J. Booser and Claire F. Verschraegen. Their work appears in journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment, Cancer Research, BMC Cancer and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact